Press Releases

Alios BioPharma to Present Preclinical Data on its Anti-HCV Nucleotides AL-335 and AL-516
November 06, 2014
Read More...

Alios BioPharma Presented Positive Results of its Anti-RSV Nucleoside Analog AL-8176
October 13, 2014
Read More...

Alios BioPharma Announces Acquisition Agreement with Johnson & Johnson
September 30, 2014
Read More...

Alios BioPharma Presents Data on its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C
September 15, 2014
Read More...

Alios BioPharma Announces Upcoming RSV & HCV Scientific Presentations
September 11, 2014
Read More...

Alios BioPharma Reports Positive Results of its Anti-RSV Nucleoside Analog AL-8176 in a Phase 2
July 23, 2014
Read More...

Alios BioPharma Raises $41 Million in Series B Financing
April 07, 2014
Read More...

Alios BioPharma Reports Significant Progress With Its Clinical Program for AL-8176
January 13, 2014
Read More...

Alios BioPharma Initiates Phase 1 Clinical Trial for Respiratory Syncytial Virus (RSV) Infection
May 30, 2013
Read More...

Alios BioPharma Presented Data on Its First-in-Class Anti-Respiratory Syncytial Virus
October 01, 2012
Read More...

Vertex Announces New Data on ALS-2200 and Ends Development of ALS-2158
September 25, 2012
Read More...

Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200
July 30, 2012
Read More...

Alios BioPharma, Inc. and Versitech Ltd. Announce Exclusive Agreement
October 31, 2011
Read More...

Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement
June 13, 2011
Read More...

Alios BioPharma Issued Broad U.S. Patent for Glyco-engineered Interferons
October 16, 2009
Read More...

Alios BioPharma, Inc. has appointed Plexxikon Founder and Chief Executive Officer K. Peter Hirth, Ph
August 13, 2009
Read More...

Alios BioPharma, Inc. Closes $32 Million Series A Financing
June 11, 2009
Read More...

Alios BioPharma, Inc. Completes First Closing of Series A Financing with Commitment of $24 MM from 3 Top-Tier Investors
February 12, 2009
Read More...

Dr. Lawrence Blatt presents at C21 Bio Ventures conference; May 21-22, 2008
May 23, 2008
Read More...

DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY
May 16, 2008
Read More...

Alios BioPharma Licenses RNase L Activators from Cleveland Clinic for Antiviral and Anticancer Therapeutics -- Company Plans to Develop New Class of Broad Spectrum Drugs for the Treatment of Viral Diseases and Cancer --
November 20, 2007
Read More...